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Validation of the IPF-specific version of St.
George’s Respiratory Questionnaire
Thomas Skovhus Prior1* , Nils Hoyer2, Saher Burhan Shaker2, Jesper Rømhild Davidsen3, Janelle Yorke4,
Ole Hilberg5 and Elisabeth Bendstrup1
Abstract
Background: Patients with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL). To
measure HRQL, an IPF-specific version of the St. George’s Respiratory Questionnaire (SGRQ-I) was developed, but
not sufficiently validated. This study aimed to assess the validity (i.a. known-groups validity and concurrent validity)
and test-retest reliability of SGRQ-I in IPF patients with different disease durations.
Methods: Patients with IPF were consecutively recruited and completed SGRQ, SGRQ-I, King’s Brief Interstitial Lung
Disease questionnaire (K-BILD), University of California, San Diego Shortness of Breath Questionnaire (SOBQ) and
Short Form-36 (SF-36) along with pulmonary function tests and a 6-min walk test (6MWT) at baseline. After two
weeks, SGRQ-I and Global Rating of Change Scales (GRCS) were completed.
Results: At baseline and after two weeks, 150 and 134 patients completed the questionnaires, respectively. The
internal consistency of SGRQ-I was high (Cronbach’s α = 0.92). Good concurrent validity was demonstrated by
high intraclass correlation coefficients (ICC = 0.97), Bland-Altman plots and moderate to strong correlations to
K-BILD, SOBQ and SF-36 (r = − 0.46 to 0.80). High ICC (0.92) and a Bland-Altman plot indicated good
test-retest reliability. SGRQ-I was good at discriminating between patients with different stages of disease
(Δscore > 18.1, effect sizes > 0.10). Validity was similar across groups of different disease duration.
Conclusions: SGRQ-I proved to be valid at distinguishing between different disease severities, valid compared
to other HRQL instruments, applicable across different disease durations and reliable upon repetition. SGRQ-I
is a valid option for measuring HRQL in patients with IPF.
Trial registration: The study was registered at clinicaltrials.org (NCT02818712) on 15 June 2016.
Keywords: Interstitial lung disease, Idiopathic pulmonary fibrosis, Health-related quality of life, Quality of life,
IPF-specific version of the St. George’s respiratory questionnaire, SGRQ-I, SGRQ, K-BILD
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive
interstitial lung disease (ILD) with a poor prognosis [1].
Patients with IPF experience both physical and psycho-
logical deficits including dyspnea, reduced exercise cap-
acity, social isolation and loss of mental well-being [2].
These symptoms inevitably affect the quality of life of
patients with IPF.
Health-related quality of life (HRQL) expresses of the
impact of a patient’s health status on his or her quality
of life. As the current treatments for IPF do not signifi-
cantly reduce mortality [3, 4], improving HRQL is
becoming an important outcome in both clinical trials
and daily clinical practice. HRQL can be measured using
both generic and disease-specific instruments [5]. Dis-
ease-specific instruments have been designed to assess
aspects of health status particularly relevant to the dis-
ease of interest. This improves the relevance of the items
of the instrument to patients and will probably make
them more responsive to changes than generic
instruments [5].
Often, non-IPF specific instruments have been used to
assess HRQL in patients with IPF e.g. the St. George’s
Respiratory Questionnaire (SGRQ) [3, 6]. SGRQ was
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originally developed for patients with obstructive lung
diseases [7, 8], but due to a lack of disease-specific HRQL
instruments, SGRQ has been widely used in patients with
IPF. Even though SGRQ holds acceptable validity and reli-
ability in patients with IPF, some items are less relevant to
this patient group and possesses weaker psychometric
properties [7]. Among these, especially the symptoms do-
main including questions about attacks of chest trouble
and wheezing are less relevant to patients with IPF.
An IPF-specific version of the SGRQ (SGRQ-I) was
developed based on a cohort of patients with IPF [9]. Of
the 50 items in SGRQ, the 34 items which were most
reliable for measuring HRQL in patients with IPF were
retained in SGRQ-I. However, important aspects of val-
idity have not been assessed in SGRQ-I. To our know-
ledge, no previous studies have examined the ability of
SGRQ-I to distinguish between patients with different
stages of disease severity. This is a substantial part of
validity, as the instrument should be able to discriminate
patients with advanced disease from patients in early
disease states. Neither has SGRQ-I been compared to a
dyspnea instrument which is validated for use in patients
with IPF nor to another ILD-specific HRQL instrument.
A number of instruments are used to measure dyspnea,
but the University of California, San Diego Shortness of
Breath Questionnaire (SOBQ) is one of the best vali-
dated instruments for use in patients with IPF [10, 11].
The King’s Brief Interstitial Lung Disease questionnaire
(K-BILD) is an ILD-specific instrument measuring
HRQL that has high validity in patients with IPF [12]. By
comparing SGRQ-I to such instruments, the validity of
the questionnaire can be strengthened. Furthermore,
test-retest reliability of SGRQ-I has only been examined
in a small study of 23 patients with IPF [13]. It is essen-
tial that the results of the instrument are repeatable with
minimal variation in stable patients.
To increase the generalizability and reliability of SGRQ-
I, the results of the initial validation should be repeatable
in other cohorts of patients with IPF. Also, the validity
should be examined in both patients with a recent diagno-
sis of IPF and longer disease durations. Another aspect of
generalizability is the use of instruments in other lan-
guages. So far, SGRQ-I has only been translated into
Spanish [13], and no IPF-specific HRQL instruments are
available in Danish. Translation of valid and reliable
HRQL instruments is important to support international
research in new IPF treatments and studies aiming at
uncovering determinants of HRQL in patients with IPF.
This is needed to make effective interventions targeted at
improving HRQL in patients living with this burdensome
disease. Thus, efforts might include discussing advance
care planning and palliation at an early stage in patients
with this progressive disease, which is also recommended
by the World Health Organization (WHO) [14, 15].
The aim of this study was to evaluate the known-
groups validity and test-retest reliability of SGRQ-I,
assess the validity of SGRQ-I in patients with different
disease durations, translate SGRQ-I into Danish and
examine the correlations to SOBQ and K-BILD.
Methods
Translation and cultural adaptation
Minor parts of SGRQ were changed during the develop-
ment of SGRQ-I [9]. These passages were translated into
Danish by a stepwise forward-backward translation pro-
cedure (see Additional file 1) [16, 17]. Semi-structured
interviews with a group of patients with IPF were
performed to obtain the patients’ perspective on the
translated version of SGRQ-I. The modified versions of
SGRQ-I were reviewed by the developers during the
course of translation and at the final approval. The
SGRQ-I was composed of the translated passages and
the existing translation of SGRQ.
Design
Patients diagnosed with IPF were recruited successively
from the three tertiary ILD centres in Denmark at the
University Hospitals in Aarhus, Gentofte (Copenhagen)
and Odense. Adult patients with a guideline-based
diagnosis of IPF were eligible for inclusion [18, 19]. Both
prevalent and incident patients were included. The only
exclusion criterion was inability to complete the
questionnaires due to cognitive or linguistic barriers.
The same patient cohort was also used to validate the K-
BILD (manuscript submitted).
At baseline, patients completed SGRQ-I, SGRQ, Short
Form-36 (SF-36) and SOBQ. Fourteen days later, SGRQ-
I and Global Rating of Change Scales (GRCS) were
completed. Questionnaires missing total or domain
scores or containing more than 15% missing answers
were excluded from the analyses. Results were obtained
from pulmonary function tests (PFTs)(forced vital cap-
acity (FVC) and diffusing capacity of the lung for carbon
monoxide (DLCO)), and the 6-min walk test (6MWT),
and the gender, age and physiology (GAP) index was
calculated [20].
The study was approved by the Danish Data Protection
Agency and the Central Denmark Region Committee
of Health Research Ethics. The study was registered
at clinicaltrials.org (https://clinicaltrials.gov/ct2/show/
NCT02818712). Written and informed consent was ob-
tained from participants before enrolment in the study.
Study measures
SGRQ-I consists of 34 self-completed items measuring
HRQL [9]. It was developed as an IPF-specific version of
SGRQ. Different scales are used to score SGRQ-I and
results in a total score and three domain scores: Impacts,
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Activities and Symptoms. Scores range from 0 to 100,
with higher scores indicating more impaired HRQL.
SGRQ is a 50-item self-completed questionnaire
assessing HRQL [8]. It was developed for patients with
chronic obstructive lung disease (COPD) and asthma,
but has subsequently been validated for patients with
IPF [7]. Response options, scoring and domains are
similar to SGRQ-I. Higher scores also correspond to
more impaired HRQL.
K-BILD consists of 15 self-completed items assessing
HRQL in patients with ILD [12]. Answers are scored on
a 7-point Likert scale and results in a total score and
three domain scores: Chest symptoms, Breathlessness
and activities and Psychological. Scores range from 0 to
100, with higher scores corresponding to better HRQL.
SOBQ estimates dyspnea associated with activities of
daily living in a 24-item self-completed questionnaire
[21]. Symptoms are scored on a 6-point scale. Scores
range from 0 to 120 and higher scores denote more
dyspnea.
SF-36 contains 36 self-completed items concerning
generic quality of life and is scored on a 3–6-point
Likert scale [22]. Scoring is divided into eight domain
scores and two component scores, based on scores ran-
ging from 0 to 100. High quality of life is expressed by
high scores.
GRCS are designed to assess the current state of the
patients compared to baseline [23]. The questionnaires
are self-completed on an 11-point Likert scale.
Responses range from “Very much worse” over
“Unchanged” to “Very much better” with corresponding
numbers ranging from − 5 to 5. Four GRCS scores
composed: One for overall health status and three for
the SGRQ-I domains.
The GAP index is a prognostic staging system devel-
oped to predict mortality in patients with IPF [20]. The
index is a composite score, which is calculated based on
gender, age and 2 lung physiology variables (FVC and
DLCO). The patients are divided into three groups with
different 1-year mortalities ranging from 6 to 39%.
Validation
The interrelatedness of the items in SGRQ-I was exam-
ined to measure the internal consistency of the question-
naire. Concurrent validity was evaluated by comparing
SGRQ-I to SGRQ, K-BILD, SOBQ, SF-36, PFTs and dis-
tance walked during the 6-min walk test (6MWD). Test-
retest reliability was evaluated by comparing the SGRQ-I
scores at baseline and after two weeks in stable patients.
Known-groups validity was evaluated by estimating the
ability of the SGRQ-I to distinguish groups of patients
with different stages of disease severity. Stratification of
patients into “known groups” of disease severity was per-
formed in accordance with their PFTs (FVC and DLCO
divided into quartiles), supplement of long-term oxygen
therapy (LTOT) and their GAP index [24].
Statistical analysis
Patients were categorized into three groups in accord-
ance with the time since diagnosis of IPF (TSD): < 1
month, 1–12 months and > 12months. The thresholds
were chosen to reflect newly diagnosed patients, patients
with a short disease duration and, lastly, patients with a
longer disease duration.
Fisher’s exact test for binomial data was used to com-
pare the characteristics of non-responders vs. responders
of the questionnaires at baseline and after two weeks.
Cronbach’s α was calculated for each domain and total
score to assess the internal consistency of SGRQ-I.
Results above 0.7 are regarded as reliable internal
consistency [25].
Concurrent validity was examined by intraclass correl-
ation coefficients (ICCs) and Bland-Altman plots for
comparison of SGRQ-I and SGRQ, and Pearson’s correl-
ation coefficients were used to compare SGRQ-I to the
other measures after evaluation of linearity. Test-retest
reliability was also evaluated by ICCs and Bland-Altman
plots after assessment of normality. Patients scoring − 1
to 1 in GRCS two weeks after baseline were considered
stable. ICC values above 0.7 are accepted as valid
measures of equivalence and reliability [25].
Continuous data were analysed by the independent
two-sample t-test when normally distributed, and by the
Wilcoxon-Mann-Whitney test when not normally
distributed. Linear regression analysis was applied for
comparison of GAP groups, and the model was checked
by diagnostic plots of the residuals. Analysis of variance
(ANOVA) or multiple linear regression was performed
to subsequently calculate effect size, reported as partial
η2: 0.01 = small effect, 0.06 = medium effect and 0.14 =
large effect [26]. Bartlett’s test for equal variances and
diagnostic plots of the residuals were used for model
checking of ANOVA.
Quantile-quantile plots (QQ-plots) were used to
assess normality, and the F-test was used to assess
variance homogeneity. Data were analysed using
STATA, version 14.2.
Results
Translation and cultural adaptation
The permission to translate SGRQ-I was obtained from
the developers of the original instrument [9]. The
Danish version of SGRQ-I was accepted with a minor
revision by the developers, after the forward-backward
translation procedure. Semi-structured interviews of a
representative group of five patients with IPF (see
Additional file 2) were performed after completing the
Danish version of SGRQ-I. The patients thought the
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SGRQ-I was comprehensive with a high face and
content validity. No changes were made to the Danish
version after the interviews (see Additional file 3).
Psychometric validation
Between August 2016 and March 2018, 150 patients
with IPF were included in the study from the three
tertiary ILD centers in Denmark (110 patients in Aarhus,
24 in Gentofte and 16 in Odense). Demographics of the
patients are presented in Table 1.
The number of questionnaires missing domain or
total scores or comprising more than 15% missing
answers at baseline were: SGRQ-I (2 missing, 1.3%),
K-BILD (1 missing, 0.7%), SOBQ (3 missing, 2.0%),
SGRQ (2 missing, 1.3%) and SF-36 (1 missing, 0.7%).
Only one item had a substantial number of missing
answers (I1, 49,3% missing) (see Additional file 4).
After two weeks, nine patients had more than 15%
missing answers and seven patients did not complete
the questionnaires (4.7%). Missing data analyses
revealed no differences between responders and non-
responders at baseline (see Additional file 5). After
two weeks, statistically significant differences were
weak and only included smoking status (p = 0.03) and
6MWD (p = 0.04). Responders after two weeks walked
on average 62.7 m longer than non-responders during
the 6MWT. There were more former smokers among
the responders and more current and never smokers
among the non-responders (see Additional file 5). No
floor or ceiling effects were observed in neither
SGRQ-I total nor domain scores, as < 15% of the
patients obtained the highest or lowest possible
scores, respectively [27].
Internal consistency
Cronbach’s α was high in both total and domain scores
of SGRQ-I indicating a good internal consistency
(Table 2). The results were comparable in the TSD sub-
groups (data not shown), except for the symptoms do-
main having a slightly smaller Cronbach’s alpha value of
0.67.
Concurrent validity
Agreement between SGRQ-I and SGRQ measured by
ICCs was good in the symptoms domain and excellent
in the total and other domain scores (Table 2). Bland-
Altman plots supported these findings, even though
SGRQ-I tended to score a bit higher in the symptoms
and activities domains and there was a slight incline in
the difference between the two scores with increasing
average scores (Fig. 1). Correlations to K-BILD, SOBQ
and SF-36 were mainly moderate to strong, while corre-
lations were weaker to PFTs and 6MWD (Table 3).
Overall, these findings indicate a good concurrent
validity.
The three TSD subgroups had similar ICCs and correla-
tions, apart from the 6MWD and DLCO. Correlation
between DLCO and the activities domain was weaker for
patients with an IPF diagnosis < 1month (− 0.21). 6MWD
had weaker correlations to the activities and impacts do-
mains in patients with an IPF diagnosis < 1month (− 0.04
and − 0.26, respectively). Overall, these findings indicate a
good concurrent validity.
Test-retest reliability
Most patients were stable in overall health status as well
as in the three domains of SGRQ-I, as evaluated by
GRCS after two weeks. A good test-retest reliability of
SGRQ-I was seen in the stable patients by high ICC
values and a Bland-Altman plot when comparing
answers at baseline and after two weeks (Table 4 and
Fig. 2). The results were comparable across the TSD
groups (data not shown).
Table 1 Baseline demographics of participants (n = 150)
Characteristics Value
Male (%) 122 (81.3%)
Age, years ± SD 72.9 ± 6.2
Smoking status
Never (%) 40 (26.6%)
Former (%) 101 (67.3%)
Current (%) 9 (6.0%)
Time since diagnosis, years (interquartile range) 0.5 (0.0–9.2)
< 1 month 0.0 (0.0–0.02)
1–12 months 0.5 (0.3–0.8)
> 12 months 2.8 (1.8–4.0)
FVC, % predicted ± SD 87.2 ± 23.1
DLCO, % predicted ± SD 48.4 ± 14.1
6MWD, m ± SD 450.3 ± 112.5
Long-term oxygen therapy (%) 19 (12.7%)
Values are presented as n (%), mean ± standard deviation (SD) or mean with
interquartile range. FVC: Forced vital capacity; DLCO: Diffusing capacity of the
lung for carbon monoxide; 6MWD: distance walked during the 6-min walk test.
The same patients were used in a validation study of K-BILD
(manuscript submitted)
Table 2 Internal consistency and concurrent validity of SGRQ-I
SGRQ-I Cronbach’s α ICC
Total 0.92 0.97
Symptoms 0.77 0.78
Activities 0.86 0.94
Impacts 0.84 0.96
Data are presented as Cronbach’s alpha and intraclass correlation coefficients
(ICC) of the total and three domain scores of SGRQ-I compared to SGRQ for all
patients. SGRQ-I: IPF-specific version of the St. George’s
Respiratory Questionnaire
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Fig. 1 Bland-Altman plot of the agreement between SGRQ-I and SGRQ for all patients. The solid line is the mean difference, while the
dashed lines are the 95% limits of agreement. SGRQ-I: IPF-specific version of the St. George’s Respiratory Questionnaire; SGRQ: St. George’s
Respiratory Questionnaire
Table 3 Concurrent validity of SGRQ-I
SGRQ-I Total SGRQ-I Symptoms SGRQ-I Activities SGRQ-I Impacts
K-BILD total −0.76* − 0.58* − 0.71* −0.70*
K-BILD chest symptoms −0.69* −0.64* − 0.54* −0.66*
K-BILD breathlessness and activities −0.78* −0.57* − 0.76* −0.70*
K-BILD psychological −0.58* −0.47* − 0.52* −0.55*
SOBQ total 0.80* 0.54* 0.74* 0.76*
SF-36 PCS −0.71* − 0.50* −0.63* − 0.68*
SF-36 MCS −0.46* − 0.40* −0.34* − 0.46*
FVC% −0.30* − 0.32* −0.20* − 0.30*
DLCO% −0.48* − 0.28* −0.53* − 0.42*
6MWD (m) −0.50* − 0.25* −0.46* − 0.52*
All data are presented as Pearson’s correlation coefficients for all patients. *: p < 0.02. SGRQ-I: IPF-specific version of the St. George’s Respiratory Questionnaire;
K-BILD: King’s Brief Interstitial Lung Disease questionnaire; SOBQ: University of California, San Diego Shortness of Breath Questionnaire; SF-36: Short Form-36;
PCS: Physical Component Score; MCS: Mental Component Score; FVC: Forced vital capacity; DLCO: Diffusing capacity of the lung for carbon monoxide;
6MWD: Distance walked during the 6-min walk test
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Known-groups validity
SGRQ-I total scores were significantly higher in patients
in the lower quartile of FVC % predicted and DLCO %
predicted compared to patients in the upper quartile
(Fig. 3 and Additional file 6). Patients receiving LTOT
had significantly higher SGRQ-I total scores than
patients not receiving oxygen therapy. SGRQ-I total
score increased with advancing disease severity reflected
by the GAP index. Medium to large effect sizes supports
the high discriminative strength of SGRQ-I.
Discussion
SGRQ-I was translated into Danish and proved to be a
valid tool to measure HRQL with a good internal
consistency, solid concurrent validity, high test-retest
reliability and a good ability to discriminate between
patients with different stages of disease. SGRQ-I was
also equally valid in patients with different disease
durations on almost all parameters.
The known-groups validity of SGRQ-I has not previ-
ously been investigated. An important aspect of measure-
ment validity is the ability of the instrument to distinguish
between patients with different stages of disease, as HRQL
worsens with increasing disease severity [28]. Our results
show that SGRQ-I is very good at differentiating patients
with respect to pulmonary function measured by FVC and
DLCO. When stratifying patients into groups according to
the GAP index or use of LTOT, SGRQ-I was also able to
differentiate between these groups. These novel results
add further weight to the validity of SGRQ-I and empha-
sizes the relevant utility of the instrument.
Reliability was not assessed during the development of
the instrument and was only evaluated in a small group
of 23 patients in another study. Reliability is a central
part of an instrument’s measurement qualities to supply
trustworthy results. SGRQ-I proved to be very reliable
when completed twice within a short period of time in
stable patients. Apart from the limited sample size, pa-
tients were only asked for worsening of symptoms upon
completing SGRQ-I the second time [13]. We excluded
patients with both improvement and deterioration to
ensure that only truly stable patients were included in
the analysis of reliability.
In order to examine the concurrent validity, we
compared SGRQ-I to SGRQ and correlated SGRQ-I to
other HRQL instruments and measurements of disease
severity relevant to IPF. The ICCs were high for both
domain and total scores, indicating very good agreement
between SGRQ-I and SGRQ. The Bland-Altman plots
supported these findings, even though there was a
tendency towards slightly higher scores in SGRQ-I com-
pared to SGRQ with increasing average scores. As such,
SGRQ-I scores indicate a broader spectrum of HRQL, as
patient have better HRQL measured by SGRQ-I than by
SGRQ with low average scores and worse HRQL with
higher average scores. This may be due to the removal
Table 4 Test-retest reliability of SGRQ-I
SGRQ-I n ICC
Total 99 (73.9%) 0.92
Symptoms 105 (78.4%) 0.81
Activities 104 (77.6%) 0.80
Impacts 104 (77.6%) 0.79
Data represent number of stable patients (% of responders, n = 134) and
intraclass correlation coefficients (ICCs). SGRQ-I: IPF-specific version of the
St. George’s Respiratory Questionnaire
Fig. 2 Bland-Altman plot of the repeatability of SGRQ-I in all stable patients. The solid line is the mean difference, while the dashed lines are the
95% limits of agreement. SGRQ-I: IPF-specific version of the St. George’s Respiratory Questionnaire
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of selected item with poor fit to the Rasch model or
many missing answers in patients with IPF [9]. If the
two instruments had very similar results, the justification
for SGRQ-I would only lie in face and content validity.
Based on these results, one could argue that SGRQ-I
should be used instead of SGRQ in patients with IPF, as
the results differ slightly and SGRQ-I is targeted at IPF.
The validity of SGRQ-I is also supported by the strong
correlations to K-BILD. After all, comparing SGRQ-I to
an ILD-specific HRQL instrument provides better evi-
dence of the validity than comparisons to instruments
developed for other lung diseases.
Compared to SGRQ, the SGRQ-I holds a pronounced
advantage as it only consists of 34 items compared to 50
items in the SGRQ. It is easier to complete and has the
same validity and reliability as SGRQ. Nevertheless, both
instruments are more suitable for research purposes
than clinical assessments. A Tool to Assess Quality of
life in IPF (ATAQ-IPF) is another IPF-specific HRQL
instrument containing 74 items [29]. ATAQ-IPF covers
more domains than SGRQ-I but is also more time
consuming to complete which may limit its use. As such,
SGRQ-I should be considered as an IPF-specific HRQL
instrument in future clinical trials. Other HRQL
questionnaires validated for IPF and other ILDs include
K-BILD and the COPD Assessment Test (CAT). K-BILD
consists of 15 items and has validity and reliability com-
parable to SGRQ-I [12]. CAT was developed for patients
with COPD, but has subsequently been validated in IPF
and other ILDs [30–32]. However, as SGRQ-I is more
comprehensive than both K-BILD and CAT, doctors and
healthcare professionals will have a better impression of
the disabilities and limitations experienced by the
patients in their daily living. Hence, it will be easier to
intervene and assist the patients in an attempt to
improve their everyday HRQL.
Dyspnea is a major symptom in IPF and correlations
to SOBQ were generally strong, demonstrating a good
Fig. 3 SGRQ-I total score in (a) the lower and upper quartile of FVC % predicted, (b) the lower and upper quartile of DLCO % predicted, (c) long-
term oxygen therapy and (d) GAP index. The midlines in the boxes are the median values and the boundaries are the 25th and 75th percentiles;
the whiskers are the upper adjacent values (1.5 interquartile range above the 75th percentile) and lower adjacent values (1.5 interquartile range
below the 25th percentile). The dots are outlying values. SGRQ-I: IPF-specific version of the St. George’s Respiratory Questionnaire. FVC: Forced
vital capacity; DLCO: Diffusing capacity of the lung for carbon monoxide; LTOT: Long-term oxygen therapy; GAP: Gender, age, physiology
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reflection of this symptom in SGRQ-I. In the original
version, dyspnea was measured using the Borg dyspnea
index and the baseline dyspnea index (BDI). The correl-
ation of SGRQ-I total score to SOBQ was stronger than
the correlations to Borg scale and BDI (0.80 vs 0.46 and
− 0.67, respectively). SOBQ has been validated for use in
patients with IPF [10, 11] and covers dyspnea associated
with a wide range of daily activities. As such, SOBQ may
be a better measure of dyspnea in IPF than Borg and
BDI, and SGRQ-I seem to capture the severity of
dyspnea very well.
Correlations to the generic SF-36 confirmed the con-
current validity of SGRQ-I, although the correlations
were mainly weaker than correlations to the other
HRQL instruments. This is probably caused by the
generic nature of the SF-36, which has to be applicable
across a wide range of conditions and is not tailored to
reflect the symptoms and implications of living with for
instance IPF in the same way as disease-specific HRQL
instruments. The mental component score had weaker
correlations than the physical component score. Com-
parable result were obtained in the initial development
and validation of SGRQ-I [9]. As the psychological
domain of K-BILD also had weaker correlations to
SGRQ-I, the psychological impact of living with IPF may
be more diffuse and difficult to incorporate into a HRQL
instrument than the physical symptoms accompanying
IPF.
Correlations to FVC were weaker than correlations to
DLCO and 6MWD. Even though SGRQ-I had moderate
correlations to PFT results and 6MWD, these measures
only estimate the physiological limitations of IPF and
not the full impact of IPF on the patients’ lives. Similarly,
moderate to weak correlations have been demonstrated
in other HRQL questionnaires including SGRQ, K-BILD
and ATAQ-IPF [7, 12, 29]. Therefore, HRQL instru-
ments are important supplements for both clinical trials
and daily clinical practice to get a full picture of the
current state of patients with IPF.
This study included the largest number of patients in a
translation and validation study of SGRQ-I, which has
previously only been translated into Spanish in a popula-
tion of only 23 patients [13]. By including a larger cohort
of patients, the generalizability of our results increases,
as the study population is more likely to reflect the back-
ground population in terms of disease severity, socio-
economic status and views on life. Our results support
the former findings indicating that SGRQ-I is a valid
and reliable measure of HRQL [9, 13]. Also, SGRQ-I
proved to be equally valid in patients with different
disease durations which is a novel finding. The weaker
correlations of the activities and impacts domains to
DLCO and 6MWD in incident patients do not signifi-
cantly change these results.
SGRQ-I is currently the only tool in Danish to meas-
ure HRQL explicitly developed for patients with IPF.
The questionnaire was both well-received and perceived
as relevant by patients with IPF. The Danish version of
SGRQ-I was comparable to the original English version
and as such, SGRQ-I performed well in a non-English
speaking population.
Responders and non-responders were comparable
regarding demographics, LTOT, medical treatment or
PFTs in the missing data analyses at baseline. After two
weeks, the only significant differences were smoking
status and 6MWD. Though these results could indicate
some degree of healthy volunteer bias, however, as dif-
ferences between the two groups were minimal, we pre-
sume that no significant selection bias was introduced.
The large number of participants is a clear strength of
our study. Also, the fact that the patients were recruited
in a multicenter setup increased the generalizability of
the results with a better reflection of the background IPF
population. Furthermore, we assessed many different as-
pects of validity and reliability, including comparisons to
both other HRQL instruments and measures of disease
severity. A limitation of our study is the single measure-
ment of pulmonary function and level of physical activ-
ity. Symptoms can vary from day to day, and repeated
measurements at home, e.g. with home spirometry or
accelerometers, might give a better impression of the
true physical functional state of the patients.
Conclusions
SGRQ-I is a valid measure of HRQL in patients with IPF
that can be utilized in patients with different disease
durations. SGRQ-I can discriminate between patients
with different stages of disease severity and is reliable
upon repeated measurements in stable patients. The
impact of dyspnea on HRQL is well represented in
SGRQ-I and HRQL measured by SGRQ-I reflect the re-
sults of another ILD-specific HRQL instrument. Transla-
tion of SGRQ-I into another language with equal validity
is feasible. Due to the poor prognosis of IPF and its
progressive nature, HRQL is an important outcome in
both daily clinical practice and clinical trials. As SGRQ-I
is shorter than SGRQ but equally valid and reliable,
SGRQ-I is an improvement and a better option for use
in future clinical trials.
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